johnson & johnson featured image
News Pharmaceutical & Biotech Stories

Johnson & Johnson’s Single-Dose Vaccine Enters Late-Stage Trials

Pharmaceutical titan Johnson & Johnson has begun its phase three trial testing its potential coronavirus vaccine in 60,000 people enrolled in the trial.

J&J’s vaccine was designed using the same technology from their Ebola vaccine, which combines genetic material from the COVID-19 virus with an altered adenovirus, the virus that causes the common cold in people.

According to the National Institute of Allergy and Infectious Diseases, the trial will enroll up to 60,000 adult volunteers across 215 locations in the U.S and other countries.

“Four COVID-19 vaccine candidates are in Phase 3 clinical testing in the United States just over eight months after SARS-CoV-2 was identified,” Institute Director Dr. Anthony Fauci said in a statement.

“This is an unprecedented feat for the scientific community made possible by decades of progress in vaccine technology and a coordinated, strategic approach across government, industry, and academia,” he said.

“It is likely that multiple COVID-19 vaccine regimens will be required to meet the global need. The Janssen candidate has shown promise in early-stage testing and may be especially useful in controlling the pandemic if shown to be protective after a single dose.”

J&J previously said it anticipates possible vaccine batches for a potential emergency use authorization available in early 2021. The company said it has continued the scaling up of its manufacturing capacity and remains on track to meet its goal of providing a billion doses of a vaccine each year.